Federated Hermes’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
Other funds holding ELVN
Federated Hermes's ELVN Position: Q3 2026 in Review
Federated Hermes opened a new position in Enliven Therapeutics (ELVN) in Q3 2026: 271 shares worth $12.4K. The stake represents ﹤0.01% of the portfolio and ranks #1803 among its holdings. This is a return to the name: Federated Hermes previously reported a position in ELVN as recently as Q3 2025.
Federated Hermes first reported a position in ELVN in Q3 2021 and has held it in 12 quarters since. The position peaked at $2.64M in Q4 2024. 216 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.
- Federated Hermes held 271 shares of Enliven Therapeutics worth $12.4K as of Q3 2026.
- Enliven Therapeutics was a new Federated Hermes position in Q3 2026.
- Enliven Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q3 2026, its #1803 holding.
- Federated Hermes first reported a position in Enliven Therapeutics in Q3 2021 and has held it in 12 quarters since.
- Federated Hermes's Enliven Therapeutics position peaked at $2.64M in Q4 2024.
- 216 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.
Based on Federated Hermes's 13F filing for Q3 2026, filed 12 Nov 2026.